leisure time -WSS

leisure time

author：Wikipedia 2025-10-04 04:01:31 - browse：64

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Global cancer cases to surge 77% by 2050, WHO report says

knowledge

WSS

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Surgery pushed Ben Carson to fame

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Clinical trials giant ICON acquires HumanFirst

The CDC's new social media misinformation war

House looks to weaken Medicare negotiation

knowledge

leisure time

hotspot

Virginia high school admissions case could be legal follow

Flu vaccine offering decent levels of protection this winter, new data show

New air purifier tech could be key to improving indoor air quality

Medical device lobby: We're tired of waiting on Medicare coverage

Duchenne breakthrough therapy leaves behind pioneering families

AstraZeneca loses challenge to Medicare drug price negotiation

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Duchenne breakthrough therapy leaves behind pioneering families

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

focus

How to fix the rural physician shortage in the U.S.

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Adopting new red light myopia treatments may be short

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Surgery pushed Ben Carson to fame

Gene therapy for Afghan refugees’ infant will be fully covered

focus

hotspot

knowledge

knowledge